157 completed, 39 terminated, 22 unknown, 11 withdrawn. 126 Phase 2, 47 Phase 3, 25 Phase 1, 11 Not applicable.
Follow Gynecologic Oncology Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) NP-G2-044, PLD - Platinum-resistant Ovarian Cancer | Phase 2 / Phase 3 | Active not recruiting | Novita Pharmaceuticals, Inc. | 380 | 2025-12-29 | 2026-03-09 |
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2 - Ovarian Neoplasm, Fallopian Tube Neoplasms | Phase 3 | Active not recruiting | Corcept Therapeutics | 381 | 2022-06-29 | 2026-09-25 |
| Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Pembrolizumab, Carboplatin, Paclitaxel - Endometrial Neoplasms | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 990 | 2021-01-10 | 2026-09-18 |
| Abemaciclib and Letrozole to Treat Endometrial Cancer Abemaciclib, Letrozole - Endometrial Cancer | Phase 2 | Active not recruiting | Gynecologic Oncology Group | 53 | 2020-10-10 | 2026-03-09 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Oregovomab, Paclitaxel, Carboplatin - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 3 | Active not recruiting | CanariaBio Inc. | 615 | 2020-08-25 | 2026-04-01 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression Mirvetuximab Soravtansine, Paclitaxel, Topotecan - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Completed | AbbVie | 453 | 2019-12-31 | 2025-08-27 |
| Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer Niraparib, Dostarlimab - Ovarian Neoplasms | Phase 2 | Terminated | Tesaro, Inc. | 41 | 2019-10-03 | 2022-09-10 |
| Clinical Effectiveness of First Trimester Pre-eclampsia Screening Program. pre-eclampsia screening program - Pre-eclampsia | Unknown | Far Eastern Memorial Hospital | 2000 | 2019-06-10 | 2023-03-29 | |
| Ribociclib and Letrozole Treatment in Ovarian Cancer Ribociclib, Letrozole - Low Grade Serous Carcinoma | Phase 2 | Active not recruiting | Gynecologic Oncology Group | 51 | 2019-05-20 | 2025-12-23 |
| Ketohexokinase Isoforms in Endometrial Cancer. ketohexokinase - Endometrial Cancer | Unknown | Far Eastern Memorial Hospital | 220 | 2019-04-11 | 2023-09-15 | |
| Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Pembrolizumab, Placebo for pembrolizumab, Carboplatin - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1367 | 2018-12-18 | 2026-08-19 |
| A Trial of Tisotumab Vedotin in Cervical Cancer tisotumab vedotin - Cervical Cancer | Phase 2 | Completed | Seagen Inc. | 102 | 2018-06-12 | 2023-07-25 |
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Rucaparib, Nivolumab, Placebo Oral Tablet - Epithelial Ovarian Cancer, Primary Peritoneal | Phase 3 | Active not recruiting | pharmaand GmbH | 1097 | 2018-05-14 | 2025-06-24 |
| The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer G9a protein - Vulvar Cancer, G9a Protein | Unknown | Far Eastern Memorial Hospital | 30 | 2018-04-20 | 2023-03-29 | |
| A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Niraparib, Placebo - Ovarian Neoplasms | Phase 3 | Active not recruiting | Tesaro, Inc. | 733 | 2016-07-11 | 2026-03-10 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 3 | Completed | ImmunoGen, Inc. | 366 | 2016-03-02 | 2020-10-14 |
| Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer ADXS11-001, Placebo - High Risk Cervical Cancer, Advanced Cervical Cancer | Phase 3 | Terminated | Advaxis, Inc. | 110 | 2015-12-15 | 2023-03-14 |
| Pazopanib for Treating Uterine Leiomyosarcoma Pazopanib - Uterine Leiomyosarcoma | Phase 2 | Withdrawn | Gynecologic Oncology Group | 2015-03-01 | 2015-11-18 | |
| IRCI Gynae Sarcomas, High Grade Uterine Sarcoma Cabozantinib, Placebo - Uterine Sarcoma | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 58 | 2015-02-02 | 2025-08-01 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 / Phase 3 | Unknown | Gynecologic Oncology Group | 469 | 2014-03-17 | 2021-09-30 |
Showing 20 of 238. Sign in to see all of them.
Ovarian Neoplasms (86) · Carcinoma, Ovarian Epithelial (58) · Fallopian Tube Neoplasms (53) · Uterine Cervical Neoplasms (49) · Endometrial Neoplasms (26) · Brenner Tumor (24) · Sarcoma (12) · Vulvar Neoplasms (12) · Neurotoxicity Syndromes (6) · Uterine Cervical Dysplasia (5) · Gestational Trophoblastic Disease (4) · Hydatidiform Mole (4) · Lymphedema (4) · Breast Neoplasms (3) · Fatigue (3)
Paclitaxel (46) · Cisplatin (43) · Carboplatin (27) · Taxes (17) · Gemcitabine (16) · Topotecan (14) · Radiotherapy (13) · Docetaxel (12) · Filgrastim (12) · Brachytherapy (11) · Doxorubicin (10) · Pemetrexed (9) · pegfilgrastim (7) · 1,2-diaminocyclohexaneplatinum II citrate (6) · Bevacizumab (6)
United States (217) · Canada (41) · Norway (14) · Spain (13) · United Kingdom (11) · Australia (10) · Belgium (10) · Italy (10) · Japan (10) · Taiwan (10) · South Korea (9) · France (8) · Czechia (7) · Germany (6) · Israel (6)
David S. Miller, MD (9) · Peter G. Rose, MD (7) · D. McMeekin (5) · Allan Covens, MD (4) · Don Dizon (4) · Paula M. Fracasso, MD, PhD (4) · Russell J. Schilder, MD (4) · Agustin Garcia, MD (3) · Bradley J. Monk, MD (3) · Bradley Monk (3) · David Miller, MD (3) · Deborah K. Armstrong, MD (3) · Harry J. Long, MD (3) · Higinia R. Cardenes, MD, PhD (3) · Russell Schilder (3)
PMID 30633128, PMID 11230468, PMID 12051882, PMID 12586591, PMID 12694653, PMID 12713990, PMID 12798713, PMID 12821360, PMID 14534883, PMID 14615449, PMID 14751144, PMID 14766260, PMID 15122083, PMID 15169803, PMID 15310778, PMID 15589582, PMID 15589587, PMID 15721421, PMID 15721430, PMID 15911864, PMID 15911865, PMID 15975638, PMID 15975641, PMID 15978659, PMID 16051328, PMID 16061871, PMID 16110020, PMID 16150481, PMID 16216315, PMID 16230678, PMID 16249022, PMID 16271750, PMID 16325893, PMID 16330675, PMID 16368440, PMID 16394300, PMID 16400639, PMID 16412499, PMID 16446331, PMID 16478630, PMID 16515585, PMID 16626792, PMID 16631245, PMID 16643994, PMID 16712905, PMID 16815535, PMID 16889823, PMID 16900525, PMID 16959305, PMID 17033909
U10CA027469 (89), U10CA180868 (26), U10CA101165 (18), U10CA037517 (3), U10CA180830 (3), P50CA134254 (2), R01CA071754 (2), R21CA133295 (2), UG1CA189867 (2), 2015 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1), R21CA135467 (1)